<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062841</url>
  </required_header>
  <id_info>
    <org_study_id>AG032298-01A1</org_study_id>
    <nct_id>NCT01062841</nct_id>
  </id_info>
  <brief_title>Targeted Infection Control in Long-term Care</brief_title>
  <official_title>Targeted Infection Control Program (TIP) to Reduce Resistant Pathogens and Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional study aimed at reducing multi-drug resistance and infections in
      nursing home (NH) residents. Each year, a staggering 1.5-2.0 million infections occur in NHs.
      Many of these infections are caused by multiple drug resistant organisms (MDROs) including
      methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE),
      and multidrug resistant Gram-negative bacilli (R-GNB). Antimicrobial resistance among common
      bacteria are adversely affecting the clinical course and exponentially increasing healthcare
      costs. Recognizing a need for action, legislators, policy makers, and consumer groups are
      advocating for pathogen-based universal preemptive screening for these MDROs, particularly
      MRSA in hospitals and NHs. However, implementing this sweeping mandate is controversial,
      costly, reactive, and not based on empirical evidence. It can result in a 10-20-fold increase
      in the number of NH residents placed in isolation precautions with the potential for reduced
      attention by healthcare workers, isolation and functional decline. The investigators proposal
      evaluates a novel focused approach between 'do nothing' and 'search all and destroy'
      strategies by targeting a subgroup of NH residents with indwelling devices who are at a high
      risk of acquiring MDROs and infections.

      The investigators hypothesize that the investigators targeted infection control program (TIP)
      will reduce MDRO colonization and infections in NH residents with indwelling devices. This
      cluster randomized trial will involve 12 NHs; 6 will be randomized to the TIP arm and 6 to
      the routine care arm. The investigators TIP intervention will include four components.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Component 1: Institute enhanced barrier precautions for all NH residents with indwelling
      devices; active screening for MDROs (monthly) using cultures collected from multiple body
      sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results
      to clinical staff and administration.

      Component 2: Structured, active surveillance for infections using standardized definitions in
      residents with indwelling devices and dissemination of results to clinical staff and
      administration.

      Component 3: A hand hygiene promotion program.

      Component 4: A structured educational program pertaining to indwelling device care for
      healthcare workers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of MDRO (Multidrug Resistant Organisms) Isolated</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
    <description>Total Number of MDROs isolated across all MDROs and all anatomic sites for all enrolled residents with indwelling devices over the duration of the study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of MRSA (Methicillin Resistant Staphylococcus Aureus) Isolated</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of VRE (Vancomycin Resistant Enterococci) Isolated</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Ceftazidime-resistant GNB (Gram-negative Bacilli) Isolated</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Ciprofloxacin-resistant GNB (Gram-negative Bacilli) Isolated</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of First Incident Urinary Catheter-associated Urinary Tract Infections</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All (First and Recurrent) Incident Urinary Catheter-associated Urinary Tract Infections</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incident Feeding Tube-associated Skin and Soft Tissue Infections</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incident Feeding-tube Associated Pneumonias</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Residents With New MRSA (Methicillin Resistant Staphylococcus Aureus) Acquisition</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Residents With New VRE (Vancomycin Resistant Enterococci) Acquisition</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Residents With New Resistant GNB (Ceftazidime or Ciprofloxacin Gram-negative Bacilli) Acquisition</measure>
    <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">418</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Intervention: Targeted Infection Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Targeted Infection Control</intervention_name>
    <description>Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
    <arm_group_label>Intervention: Targeted Infection Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any short- or long-stay resident with an indwelling urinary catheter or feeding tube
             for more than 72 hours

          -  Ability to get informed consent from either the resident or his/her durable power of
             attorney

        Exclusion Criteria:

          -  Having an indwelling device for less than 72 hours

          -  Refusal of consent to get surveillance cultures and data collection by the resident or
             his/her durable power of attorney

          -  Residents who are receiving end-of-life care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lona Mody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan and partner nursing homes</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <results_first_submitted>November 30, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 29, 2016</results_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Lona Mody</investigator_full_name>
    <investigator_title>Associate Professor, Internal Medicine, Division of Geriatric and Palliative Medicine</investigator_title>
  </responsible_party>
  <keyword>Long-Term Care</keyword>
  <keyword>Nursing Homes</keyword>
  <keyword>Infection Control</keyword>
  <keyword>Multi-drug resistant pathogens</keyword>
  <keyword>Long-term care residents with in-dwelling devices</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Residents with an indwelling urinary catheter and/or feeding tube were recruited from 12 nursing homes, May 2010 - April 2013</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention: Targeted Infection Control Program</title>
          <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all nursing home residents with indwelling devices; active screening for MDRO (multidrug resistant organisms) monthly using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices. Surveillance cultures and data was collected for outcome comparison only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Indwelling Device Removed</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Residents enrolled with &gt;1 follow-up visit</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention: Targeted Infection Control Program</title>
          <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all nursing home residents with indwelling devices; active screening for MDRO (multidrug resistant organisms) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="316"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.0" spread="12.4"/>
                    <measurement group_id="B2" value="72.2" spread="13.5"/>
                    <measurement group_id="B3" value="73.1" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson's Comorbidity Score</title>
          <description>Charlson's comorbidity score is a weighted index that takes into account the number and seriousness of comorbid disease. It is a classification of comorbid conditions what might alter the risk of mortality in longitudinal studies. 19 conditions are scored with 1, 2, 3, or 6 points. Total Score Range 0 to 37, with increasing scores indicating increasing burden of comorbidity (by increased number of comorbid conditions present, or increased severity of conditions present).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.6"/>
                    <measurement group_id="B2" value="2.9" spread="2.1"/>
                    <measurement group_id="B3" value="2.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Self-Maintenance Scale</title>
          <description>Functional disability was assessed using Lawton and Brodyâ€™s physical self-maintenance scale. Patients are evaluated on their ability to perform six activities of daily living (toileting, feeding, dressing, grooming, bathing, physical ambulation), with 1 = independent, 2 = needs reminders, 3 = needs moderate assistance, 4 = needs extensive assistance, 5 = needs full assistance or resistant to care. The total physical self-maintenance scale ranges from 6 to 30, with increasing scores indicating increasing disability to perform activities of daily living.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="4.1"/>
                    <measurement group_id="B2" value="22.1" spread="4.1"/>
                    <measurement group_id="B3" value="22.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indwelling Device Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indwelling Urinary Catheter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeding Tube</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Urinary Catheter and Feeding Tube</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of MDRO (Multidrug Resistant Organisms) Isolated</title>
        <description>Total Number of MDROs isolated across all MDROs and all anatomic sites for all enrolled residents with indwelling devices over the duration of the study period</description>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Residents enrolled with &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of MDRO (Multidrug Resistant Organisms) Isolated</title>
          <description>Total Number of MDROs isolated across all MDROs and all anatomic sites for all enrolled residents with indwelling devices over the duration of the study period</description>
          <population>Residents enrolled with &gt;1 follow-up visit</population>
          <units>Total Number of MDRO isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1299"/>
                    <measurement group_id="O2" value="1732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-effects multilevel Poisson regression model was used to predict MDRO prevalence density as a function of the intervention (primary outcome), including facility as a random effect and offset by the number of anatomic sites sampled. Because we expected participants colonized at baseline to have a greater likelihood of subsequent colonization, we included participant-level baseline MDRO colonization as a fixed effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The model was adjusted for participant-specific covariates (participant-level baseline colonization with the specific MDRO, age, sex, race, and length of stay before enrollment), and NH quality ratings.</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of First Incident Urinary Catheter-associated Urinary Tract Infections</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with only a urinary catheter present and &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of First Incident Urinary Catheter-associated Urinary Tract Infections</title>
          <population>Participants with only a urinary catheter present and &gt;1 follow-up visit</population>
          <units>Number of First CAUTI</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5982"/>
                <count group_id="O2" value="4292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model using the cluster option with robust standard errors was used to predict time to the first and recurrent infections, adjusting for participant-level and facility-level covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of MRSA (Methicillin Resistant Staphylococcus Aureus) Isolated</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of MRSA (Methicillin Resistant Staphylococcus Aureus) Isolated</title>
          <population>Participants with &gt;1 follow-up visit</population>
          <units>Total Number of MRSA isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-effects multilevel Poisson regression model was used to predict MDRO prevalence density as a function of the intervention (primary outcome), including facility as a random effect and offset by the number of anatomic sites sampled. Because we expected participants colonized at baseline to have a greater likelihood of subsequent colonization, we included participant-level baseline MDRO colonization as a fixed effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The model was adjusted for participant-specific covariates (participant-level baseline colonization with the specific MDRO, age, sex, race, and length of stay before enrollment), and NH quality ratings.</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of VRE (Vancomycin Resistant Enterococci) Isolated</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of VRE (Vancomycin Resistant Enterococci) Isolated</title>
          <population>Participants with &gt;1 follow-up visit</population>
          <units>Total Number of VRE isolates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-effects multilevel Poisson regression model was used to predict MDRO prevalence density as a function of the intervention (primary outcome), including facility as a random effect and offset by the number of anatomic sites sampled. Because we expected participants colonized at baseline to have a greater likelihood of subsequent colonization, we included participant-level baseline MDRO colonization as a fixed effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The model was adjusted for participant-specific covariates (participant-level baseline colonization with the specific MDRO, age, sex, race, and length of stay before enrollment), and NH quality ratings.</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Rate Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Ceftazidime-resistant GNB (Gram-negative Bacilli) Isolated</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Ceftazidime-resistant GNB (Gram-negative Bacilli) Isolated</title>
          <population>Participants with &gt;1 follow-up visit</population>
          <units>Total Number of Ceftazidime-RGNB isolate</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-effects multilevel Poisson regression model was used to predict MDRO prevalence density as a function of the intervention (primary outcome), including facility as a random effect and offset by the number of anatomic sites sampled. Because we expected participants colonized at baseline to have a greater likelihood of subsequent colonization, we included participant-level baseline MDRO colonization as a fixed effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The model was adjusted for participant-specific covariates (participant-level baseline colonization with the specific MDRO, age, sex, race, and length of stay before enrollment), and NH quality ratings.</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Ciprofloxacin-resistant GNB (Gram-negative Bacilli) Isolated</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Ciprofloxacin-resistant GNB (Gram-negative Bacilli) Isolated</title>
          <population>Participants with &gt;1 follow-up visit</population>
          <units>Total Number of Ciprofloxacin-RGNB</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738"/>
                    <measurement group_id="O2" value="952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed-effects multilevel Poisson regression model was used to predict MDRO prevalence density as a function of the intervention (primary outcome), including facility as a random effect and offset by the number of anatomic sites sampled. Because we expected participants colonized at baseline to have a greater likelihood of subsequent colonization, we included participant-level baseline MDRO colonization as a fixed effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>The model was adjusted for participant-specific covariates (participant-level baseline colonization with the specific MDRO, age, sex, race, and length of stay before enrollment), and NH quality ratings.</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All (First and Recurrent) Incident Urinary Catheter-associated Urinary Tract Infections</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with only an indwelling urinary catheter present and &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All (First and Recurrent) Incident Urinary Catheter-associated Urinary Tract Infections</title>
          <population>Participants with only an indwelling urinary catheter present and &gt;1 follow-up visit</population>
          <units>Number of CAUTI</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9413"/>
                <count group_id="O2" value="8118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incident Feeding Tube-associated Skin and Soft Tissue Infections</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with an indwelling feeding tube present (PEG tube), and had &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incident Feeding Tube-associated Skin and Soft Tissue Infections</title>
          <population>Participants with an indwelling feeding tube present (PEG tube), and had &gt;1 follow-up visit</population>
          <units>Numer of feeding-tube SSTIs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5635"/>
                <count group_id="O2" value="5062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model using the cluster option with robust standard errors was used to predict time to the first and recurrent infections, adjusting for participant-level and facility-level covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incident Feeding-tube Associated Pneumonias</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with indwelling feeding tube present (PEG tube), and had &gt;1 follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incident Feeding-tube Associated Pneumonias</title>
          <population>Participants with indwelling feeding tube present (PEG tube), and had &gt;1 follow-up visit</population>
          <units>Number of feeding-tube associated pneu</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5635"/>
                <count group_id="O2" value="5062"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model using the cluster option with robust standard errors was used to predict time to the first and recurrent infections, adjusting for participant-level and facility-level covariates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>6.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Residents With New MRSA (Methicillin Resistant Staphylococcus Aureus) Acquisition</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit, and were at-risk to acquire new MRSA colonization (not colonized at baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Residents With New MRSA (Methicillin Resistant Staphylococcus Aureus) Acquisition</title>
          <population>Participants with &gt;1 follow-up visit, and were at-risk to acquire new MRSA colonization (not colonized at baseline)</population>
          <units>Number of Residents with New MRSA</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days at Risk</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8722"/>
                <count group_id="O2" value="7115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model was used to evaluate the effect of this intervention on an individualâ€™s risk of new MDRO acquisition, defined as the number of residents with new acquisitions per 1000 device-days at risk after adjusting for resident-level and facility-level covariates, as well as clustering by facility. Residents colonized with the specific MDRO at baseline were excluded from these analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Residents With New VRE (Vancomycin Resistant Enterococci) Acquisition</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt; 1 follow-up visit, and who were at-risk to acquire a new VRE colonization (not colonized at baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Residents With New VRE (Vancomycin Resistant Enterococci) Acquisition</title>
          <population>Participants with &gt; 1 follow-up visit, and who were at-risk to acquire a new VRE colonization (not colonized at baseline)</population>
          <units>Number of Residents with New VRE</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days at Risk</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12756"/>
                <count group_id="O2" value="11070"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A Cox proportional hazards model was used to evaluate the effect of this intervention on an individualâ€™s risk of new MDRO acquisition, defined as the number of residents with new acquisitions per 1000 device-days at risk after adjusting for resident-level and facility-level covariates, as well as clustering by facility. Residents colonized with the specific MDRO at baseline were excluded from these analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Residents With New Resistant GNB (Ceftazidime or Ciprofloxacin Gram-negative Bacilli) Acquisition</title>
        <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
        <population>Participants with &gt;1 follow-up visit, and who were at-risk to acquire a new R-GNB colonization (not colonized at baseline)</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Targeted Infection Control Program</title>
            <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Residents With New Resistant GNB (Ceftazidime or Ciprofloxacin Gram-negative Bacilli) Acquisition</title>
          <population>Participants with &gt;1 follow-up visit, and who were at-risk to acquire a new R-GNB colonization (not colonized at baseline)</population>
          <units>Number of Residents with New R-GNB</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Device-days at Risk</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7524"/>
                <count group_id="O2" value="5685"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment up to 1 year, or until study withdrawal (indwelling device removed, discharged from facility, at resident request, death), or end of study</time_frame>
      <desc>Adverse Events that were Definitely related, Probably related, Possibly related to the study were captured.
Adverse Events may include: Death, Inpatient hospitalization or prolongation of existing hospitalization, A persistent or significant disability/incapacity</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention: Targeted Infection Control Program</title>
          <description>Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
Targeted Infection Control: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lona Mody, MD, MSc</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-764-8942</phone>
      <email>lonamody@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

